In conclusion, PXA and eGBM share similar clinical characteristics but exhibit different histological features. From a molecular perspective, PXA and eGBM belong to the same category and progress through the accumulation of genetic abnormalities, including TERT-p mutations, CDKN2A/B deletions, and TP53 mutations, based on the presence of BRAF mutation; however, larger sample sizes are required for validation.
Qi et al. (2026) studied this question.